Cargando…

The effect of cariprazine on patient engagement: Post-hoc analysis of a phase 3 study in patients with predominant negative symptoms of schizophrenia

INTRODUCTION: Motivation deficit is a significant aspect of lack of improvement in patients with schizophrenia especially with predominant negative symptoms (PNS). Therefore, improvement depends not only on symptoms reduction and better social functioning but also on patient engagement which is a ke...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laszlovszky, I., Dombi, Z.B., Balogh, Á., Barabássy, Á., Vass, G., Szatmári, B., Németh, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2021
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475933/ http://dx.doi.org/10.1192/j.eurpsy.2021.1423

Ejemplares similares

Safety during polypharmacy: A post-hoc analysis examining the safety profile of cariprazine with other antipsychotics in the cross-titration phase
por: Vass, G., et al.
Publicado: (2021)

Tolerability of cariprazine in the early stage of schizophrenia: A pooled, post-hoc analysis of 4 phase ii/iii double-blind placebo-controlled trials
por: Dombi, Z.B., et al.
Publicado: (2021)

The efficacy of cariprazine in chronic schizophrenia – post hoc analyses of phase II/III clinical trials
por: Falkai, P., et al.
Publicado: (2022)

Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety
por: Laszlovszky, István, et al.
Publicado: (2021)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies
por: Barabássy, Ágota, et al.
Publicado: (2021)

Cariprazine’s efficacy in treating affective symptoms – pooled data from schizophrenia and bipolar depression trials
por: Mcintyre, R., et al.
Publicado: (2022)

The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy: an observational study
por: Rancans, Elmars, et al.
Publicado: (2021)

Disentangling the symptoms of schizophrenia: Network analysis in acute phase patients and in patients with predominant negative symptoms
por: Demyttenaere, Koen, et al.
Publicado: (2021)

Cariprazine Safety in Adolescents and the Elderly: Analyses of Clinical Study Data
por: Szatmári, Balázs, et al.
Publicado: (2020)

Dosing Cariprazine Within and Beyond Clinical Trials: Recommendations for the Treatment of Schizophrenia
por: Rancans, Elmars, et al.
Publicado: (2022)

Clinical Global Impression of Cariprazine in Negative Symptom Schizophrenia Patients: Comparison of clinical trial data vs. real-world evidence
por: Rancans, E., et al.
Publicado: (2023)

The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis
por: Nasrallah, Henry A., et al.
Publicado: (2017)

Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis
por: Durgam, Suresh, et al.
Publicado: (2017)

Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia
por: Leucht, Stefan, et al.
Publicado: (2019)

Cariprazine in the treatment of schizophrenia: a proof-of-concept trial
por: Durgam, Suresh, et al.
Publicado: (2016)

Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms
por: Vasiliu, Octavian
Publicado: (2021)

What Is the Minimum Clinically Important Change in Negative Symptoms of Schizophrenia? PANSS Based Post-hoc Analyses of a Phase III Clinical Trial
por: Czobor, Pál, et al.
Publicado: (2022)

Benzodiazepine use during cariprazine treatment in acute schizophrenia
por: Correll, C., et al.
Publicado: (2022)

Early-Onset Schizophrenia With Predominantly Negative Symptoms: A Case Study of a Drug-Naive Female Patient Treated With Cariprazine
por: Molnar, Maria Judit, et al.
Publicado: (2020)

Defining the therapeutic reference range for cariprazine
por: Kapás, M., et al.
Publicado: (2023)

Cariprazine: Patients with Treatment-Resistant Schizophrenia
por: Aubel, Thomas
Publicado: (2021)

Cariprazine hydrochloride for schizophrenia
Publicado: (2021)

Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling—an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine
por: Vokó, Zoltán, et al.
Publicado: (2020)

Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study
por: Durgam, Suresh, et al.
Publicado: (2016)

Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia
por: Culpepper, Larry, et al.
Publicado: (2022)

Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study)
por: Ivanov, Stanislav V., et al.
Publicado: (2022)

Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder
por: Vieta, Eduard, et al.
Publicado: (2019)

Cariprazine’s efficacy in treating depressive symptoms – pooled data from schizophrenia, bipolar depression and major depression trials
por: McIntyre, R. S., et al.
Publicado: (2023)

Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial
por: Fava, Maurizio, et al.
Publicado: (2018)

Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies
por: Earley, Willie, et al.
Publicado: (2017)

Combination of clozapine, cariprazine and fluoxetine in treatment-resistant schizophrenia patient with prominent negative symptoms: A Case report
por: Everte, I., et al.
Publicado: (2022)

Update on schizophrenia and bipolar disorder: focus on cariprazine
por: Roberts, Rona Jeannie, et al.
Publicado: (2016)

Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia?
por: Montgomery, Adam, et al.
Publicado: (2023)

Case series: Cariprazine in early-onset schizophrenia
por: Ivanova, Elena, et al.
Publicado: (2023)

Switching Clozapine to Cariprazine in Three Patients with Persistent Symptoms of Schizophrenia: A Case Series
por: Duque-Yemail, Juan D, et al.
Publicado: (2022)

Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine
por: Kiss, Béla, et al.
Publicado: (2019)

Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation
por: Correll, Christoph U, et al.
Publicado: (2019)

Cariprazine's Potential in Improving Social Dysfunction in Patients With Schizophrenia: A Perspective
por: Morozov, Petr, et al.
Publicado: (2022)

Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience
por: Montes, Jose M, et al.
Publicado: (2021)

Case report: Successful administration of cariprazine in a young, severely ill patient with recurrent relapses of schizophrenia and persistent negative symptoms
por: Vrublevska, Jelena
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ecdgb7qvr2jdc5rdb3c3b3e3gm